Hamamatsu, Japan

Ken-ichi Kawano


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ken-ichi Kawano: Innovator in Therapeutic Agents for Inflammatory Bowel Diseases

Introduction

Ken-ichi Kawano is a notable inventor based in Hamamatsu, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for inflammatory bowel diseases. His innovative approach has the potential to improve the quality of life for many patients suffering from these conditions.

Latest Patents

Kawano holds a patent for a therapeutic agent aimed at treating inflammatory bowel diseases. The patent describes a method for maintaining remission or treating these diseases by administering a therapeutically effective amount of 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, or a prodrug thereof. This method is particularly effective in maintaining therapy and has shown minimal side effects, even in severe cases resistant to conventional treatments.

Career Highlights

Ken-ichi Kawano is associated with Meiji Seika Kaisha, Ltd., where he continues to work on innovative solutions in the pharmaceutical field. His dedication to research and development has led to advancements that benefit patients and healthcare providers alike.

Collaborations

Kawano has collaborated with esteemed colleagues such as Tomohisa Ninomiya and Takashi Shishikura. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Ken-ichi Kawano's work in developing therapeutic agents for inflammatory bowel diseases exemplifies the impact of innovation in medicine. His contributions are paving the way for more effective treatments and improved patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…